hAstroPro Human Astrocytes Kit

add to cart
Catalog: hAP7027 $775 US | $970 International

hAstroPro™ Human Astrocyte Cells are derived from human pluripotent stem cell line h9 (NIH registry number 0062) and are the first highly characterized hESC derived CNS support cell type commercially available. hAstroPro™ cells are derived using a chemically defined method that enables shortened differentiation and scaled uniform production.

Ideal for use in studies of glial development and for use in co-culture systems with ArunA's  NeuroNet™ Pure Human Neurons.

  • Genetically uniform supply of human astrocyte cells
  • Uniform adherent astrocyte morphology
  • Express a repertoire of astrocytic genes
  • Non-transformed
  • Serum free

Contact us: info@arunabiomedical.com

 

 

 

 

 

Product Use Agreement
BIOLOGICAL PRODUCT(S) purchased and DERIVATIVE BIOLOGICAL MATERIALS resulting from the use of ArunA Biomedical BIOLOGICAL PRODUCT(S) shall not be: (i) used for any purpose other than internal research and internal research services, (ii) sold, reengineered and sold or otherwise provided to any third party for any use or purpose, (iii) provided to any agent or other third party for any reason whatsoever, or (iv) used for diagnostic or therapeutic purposes. Acceptance of these terms and conditions shall be deemed by RECIPIENT upon delivery of BIOLOGICAL PRODUCT(S) from ArunA Biomedical. 

Cell Type:  Astrocytes
Part Number:  hAP7027
Species:  human
Source:  derived from h9 hESC (NIH registry number 0062)
Morphology:  glial
Quantity:  ~1x106cells per vial
Shipping method:  dry ice
Storage:  liquid nitrogen
Growth Properties:  adherent
Medium:  AB2™ Basal Neural Medium with ANS™ Neural Medium Supplement plus additional unsupplied reagents.
Purity as determinded by qPCR: S100β, CD44, BDNF, GFAP.

Reference:

Inhibition of DNA methyltransferases and histone deacetylases induces astrocytic differentiation of neural progenitors.

Working bank DNA fingerprint:  Results are consistent with the presence of a single cell line with no evidence of culture cross contamination. The loci match the DNA fingerprint pattern for the H9 (NIH designation, ) hESC line as published in http://stemcells.nih.gov/research/nihresearch/scunit/.

Working bank pathogen testing:   This lot was derived from the H9 hESC line that has been tested for Hepatitis B, Hepatitis C, HIV-1, HIV-2, HTLV-I/II, HSV1, HSV2, EBV, and CMV.  The H9 cell line has been tested and shown to be negative (performed by GIVF Laboratories).  Cells are also tested for sterility and mycoplasma contamination.

Technical Information:

For additional information contact us at info@arunabiomedical.com or call 706-542-4941.

 

Product Use Agreement

BIOLOGICAL PRODUCT(S) purchased from ArunA Biomedical shall not be: (i) used for any purpose other than internal research and internal research services, (ii) sold or otherwise provided to any third party for any use or purpose, or (iii) provided to any agent or other third party to provide services and or other services. Acceptance of BIOLOGICAL PRODUCT(S) from ArunA Biomedical shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires ArunA Biomedical prior written authorization. BIOLOGICAL PRODUCT(S) may not be used for diagnostic or therapeutic purposes.

 

 

  

  

 

 

 

 

 

 

7 day Co culture of hN2™ Differentiated Neuronal Cells and hAstroPro™ Human Astrocyte Cells

ArunA Biomedical hN2™ Cells™

ArunA Biomedical hAstroPro™ in co-cultured with ArunA hN2™ Differentiated Neuronal Cells for 7 days

hAstroPro More representative cellular and computational model

Graph co-cultre BIS1uM


hAstroPro use in metabolomics developmental neurotoxicity assay.

A vast number of chemical entities, ranging from pesticides to compounds of therapeutic interest, remain untested for potential toxic outcomes on human neural development. Current methods for evaluating developmental neurotoxicity (DNT) rely heavily on animal based testing and non-uniform cell lines, are often prohibitively expensive, and provide suboptimal predictive value. There is thus a need for rapid, cost effective, in vitro methods to identify such chemicals. To fill this critical gap we evaluated a robust, species representative and physiologically relevant cellular system, combined with high content imaging (HCI) and metabolomics, to address human DNT. Scalable and uniform populations of undifferentiated neural progenitor cells (hNP1TM), and differentiated neurons (hN2TM) and astrocytes (hAstroProTM), derived from human embryonic stem cells (hESC) were used to represent a neurodevelopmental continuum and evaluated for toxin induced changes in neurite outgrowth, metabolomic signatures and viability. To address developmental stage specific neurotoxicity, Bis-1, a known neurotoxin, was applied to cultures pre or post neuronal differentiation, as well as in neuron-astrocyte co-cultures to represent complex brain tissue more accurately.

  • Level or stage of neural maturation differentially affects susceptibility to neurotoxins.
  • Metabolomic profiling provides a sensitive pathway analysis approach to DNT for both mature neurons, astrocytes and pre-network neural progenitors
  • Significant alteration in neuronal cellular response in co-cultures with astrocytes suggests ArunA's hAstroPro and NeuroNet cells provide a representative multi-cellular DNT model.

Click here to read more.

Your success is important to us. If you have technical questions regarding the use of your ArunA Biomedical products, we have your Tech Support Team ready. Just send an email to: techsupport@arunabiomedical.com, and a cell culture expert will assist you.

Your success is our success!

Products are to be used for research purposes only, not for use in diagnostic or therapeutic applications. It is prohibited to sell, modify for sale or use ArunA's products for commercial purposes without the express written consent of ArunA Biomedical.

ArunA has entered into a technology licensing agreement with the University of Georgia Research Foundation (UGARF) that enables the company to commercialize adherent monolayer neural cell technology developed at the University.  The license allows the company exclusive worldwide rights to develop and commercialize neural cells derived from human pluripotent stem cells including hPSC and human iPSC.

ArunA has also entered into a research and commercialization license with the Wisconsin Alumni Research Foundation (WARF) for nonexclusive rights to their embryonic stem cell patents in research applications.

 

Patent US 6,200,806

Patent US 8,178,089